COLD + SINUS TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
01-09-2020
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
可用日期:
VITA HEALTH PRODUCTS INC
ATC代码:
M01AE51
INN（国际名称）:
IBUPROFEN, COMBINATIONS
剂量:
200MG; 30MG
药物剂型:
TABLET
组成:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
给药途径:
ORAL
每包单位数:
10/20/40/50/72/96/100
处方类型:
OTC
治疗领域:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
產品總結:
Active ingredient group (AIG) number: 0222394001; AHFS:
授权状态:
APPROVED
授权日期:
2010-06-08
产品特点
Vita Health Products Inc.
Page 1
of 49
PRODUCT MONOGRAPH
COLD + SINUS
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
September 1, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control No. 242681
Vita Health Products Inc.
Page 2
of 49
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION....................................................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.....................................................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................................................
5
ADVERSE REACTIONS
...................................................................................................................................
11
DRUG INTERACTIONS
....................................................................................................................................
18
DOSAGE AND ADMINISTRATION
................................................................................................................
21
OVERDOSAGE
..................................................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................................
24
STORAGE AND STABILITY
...........................................................................................................................
28
SPECIAL HANDLING INSTRUCTION
..
阅读完整的文件
